Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 343)

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 36.576.441 von blb am 13.02.09 18:41:32

Hoff mas das los gäd!

[blb]

Antwort auf Beitrag Nr.: 36.570.539 von Ville7 am 13.02.09 07:09:48

Es geht los. Alles anschnallen!

[Ville7]

Antwort auf Beitrag Nr.: 36.569.593 von BrauchGeld am 12.02.09 22:02:26

Sehe ich auch so. Nur ein paar Hinweise darauf: Die 50er schickt sich an die 200er Linie von unten zu schneiden, die 200er stoppt zudem ihren Fall und deutet an sich zu drehen. Das anziehende Volumen spricht zudem dafür, dass andere dies auch so sehen und den Ausbruch antizipieren.

In der Regel führt das Potential dann bis maximal hin zur Oberkante des mehrjährigen Abwärtskanals. Diese Oberkante ist um die $4 herum (ich habe gerade kein Charttool, daher Ablesung per Auge). Würde uns also mittelfristig in die Zone um bis zu knapp über 3 Euro herum bringen können - je nach Dollarkurs. Das wär doch schon was..

Ein wegbrechender Gesamtmarkt oder schlechte Firmen-News könnten das Szenario aber nochmal verhindern.

[BrauchGeld]

Alles spricht dafür das wir hier bald höhere kurse sehen werden ....



http://quote.barchart.com/texpert.asp?sym=sppi&code=BSTK

[Ville7]

Antwort auf Beitrag Nr.: 36.562.376 von future_trader am 12.02.09 07:06:02

Es roch gestern nach Ausbruchsversuch. Aktuell fast $50 Mio Marktkap bei fast 50% mehr Cash als Marktkap. Das muss irgendwann korrigieren. Ziel erst mal $2.

[Ville7]

Antwort auf Beitrag Nr.: 36.558.680 von Ville7 am 11.02.09 16:20:10

Wie vermutet. Den Italienern ist das was CTIC treibt nicht koscher und sie haben das Trading ausgesetzt. NASDAQ hat nachgezogen.

--------------------

Cell Therapeutics Updates Shareholders on Trading
Wednesday February 11, 6:01 pm ET

SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that the Borsa Italiana, which is the entity that governs the trading of the Company's common stock on the MTA stock market in Milan, Italy, suddenly suspended trading of the Company's shares in Italy on February 10th. As a result of the suspension of trading by the Borsa Italiana, the security has additionally been halted on the NASDAQ Stock Market pursuant to Marketplace Rule 4120(a)(4) when a security is also registered on a foreign securities exchange and the foreign securities exchange halts trading in such security for regulatory reasons. We have not been advised of any independent basis for NASDAQ's decision to halt trading.

The Company's common stock has traded on the MTA since 2004 and is thus required to comply with the rules and regulations of the Commissione Nazionale per le Societe e la Borsa, or CONSOB, which is the public authority responsible for regulating the Italian securities markets and the Borsa Italiana, which oversees the trading market in Italy. Collectively these agencies regulate companies listed on Italy's public markets. The Company has responded to numerous requests by both the Borsa Italiana and CONSOB to provide additional clarifications about its business operations and financial condition, and the Company has met with CONSOB on several occasions, most recently on February 6th, to answer such questions. As in the past, the Company believes it has complied with CONSOB's requests to issue additional press releases in Italy and if required filed as Form 8-K in the US clarifying the information contained in the Company's SEC filings and press releases and the Company is committed to continuing to do so. The Company is waiting for clarification from the Borsa Italiana and CONSOB as to what additional information or action the Company must take, if any, for the Borsa Italiana to resume trading in Italy. The Company believes that it is currently in compliance with all undertakings for filing and reporting obligations in Italy as agreed with the Borsa Italiana and CONSOB when the shares were accepted for listing in Italy.

The Company is diligently working with the Borsa Italiana, CONSOB and the NASDAQ Stock Market to have one or both markets resume trading in the Company's common stock.

[future_trader]

scheinbar hält die Le.-Knappheit noch ein wenig an.


http://www.ashp.org/Import/PRACTICEANDPOLICY/PracticeResourc…

vielleicht auch schon bekannt.

[future_trader]

Das Volumen an der NASDAQ ist schon gewaltig gestern gewesen.

[Ville7]

Auf mittelfristige Sicht könnte ein Hersteller locker die Nachfrage an Leucovorin alleine bedienen sagt TEVA!

Wenn mit dem off-label Ersatz Fusilev gemeint ist, dann würde hier - im Gegensatz zu dem was anderswo zu lesen stand - die Versicherungen nicht für Fusilev in Colorectal Cancer zahlen! Das wäre recht negativ für Spectrum, wenn es stimmt. Schliesslich ist Fusilev sehr sehr teuer.

--------------------------

Merced cancer center sees a shortage of key drug
Companies say nationwide scarcity should be over soon.
By CAROL REITER
[e-mail]

The national scarcity of a common chemotherapy drug has one Merced cancer center scrambling to find another drug to replace it.

Leucovorin, which is mostly used on colorectal cancer patients and boosts the effectiveness of other chemotherapy drugs, is now almost impossible to find.

"We're affiliated with UC Davis, and we can't even get it from them," said June Brown, director of the Mercy Cancer Center, an affiliate of the UC Davis Cancer Network. The cancer center sees about 800 patients a year, and colorectal cancer is the fourth-most common cancer in patients it sees.

The drug is in short supply because one of the manufacturers of it ran into production problems last year. The company, Bedford Laboratories in Ohio, won't say what happened, but says it's working to expand its production capabilities.

The other company that produces the drug, Teva Pharmaceuticals in Irvine, said it could be ready to meet 100 percent of the country's demand for leucovorin within a few months, if necessary.

Meanwhile, at Mercy Cancer Center, colorectal patients are being put on a different protocol, one that may not be quite as good as the one that uses leucovorin.

"Leucovorin is a good protectant -- it allows us to give higher doses of chemotherapy," Brown said.

There's another drug that can be given instead of leucovorin, but it would have to be used off-label, and no insurance companies pay for it. In fact, Medi-Cal won't allow a patient to use it even if the patient wants to pay for it himself, or the cancer center gives it free.

Brown said that occasionally drug shortages affect the cancer center, but this one caught them by surprise. "We had enough to get our patients through their treatment to the end of December," she said.

At the Central Valley Cancer Center, Dr. Merla Puray hasn't been affected by the shortage yet, although she said warnings have come to her about coming shortages.

"We have made some arrangements to try and order ahead so we have it on hand," she said. "Fortunately, we haven't had to cut back yet."

Although the leucovorin is a standard drug for colorectal patients, Brown said there are other drugs that can do almost as good of a job, but there is one problem: They are oral drugs.

"Oral drugs have to be purchased from a pharmacy, and they're expensive," Brown said. "That's a hardship on a lot of people who just can't afford them."

[Ville7]

Die Shortage ist fast vorbei. Scheinbar haben einige Onkologen es vorgezogen ihren Patienten nur eine geringe oder keine Dosis Leucovorin zu geben als Fusilev zu bestellen.

------------------

Drug shortage keeps colon-cancer patients waiting for doses
By Robyn Shelton / The Orlando Sentinel
Tuesday, February 10, 2009 - Added 17h ago

EmailE-mail PrintablePrintable Comments(0) Comments LargerSmallerText size ShareShare Rate(0) Rate

ORLANDO, Fla. — A drug shortage has been keeping many colon-cancer patients in Central Florida and nationwide from getting a medicine that boosts the effectiveness of their chemotherapy.

Supplies of the generic drug, leucovorin, have lagged since December, when one of its two manufacturers ran into production problems, according to the Food and Drug Administration. Local oncologists have been forced at times to change treatment regimens or give people lower doses than usual.

"They tell me that I need this (medicine) to help my chemotherapy bind to the tumor better and shrink it," said colon-cancer patient Patricia DiFonzo, 65, of Casselberry, Fla. "This is a drug that a lot of people need. I just don’t understand how this can happen. Who’s minding the store?"

Leucovorin is one of 10 drugs in short supply nationally, according to information on the FDA’s Web site. Others include the chemotherapy agent cisplatin and a patch for early-stage Parkinson’s patients called Neupro.

Though not life-threatening in itself, doctors say missing a dose of leucovorin is not optimal. The drug is a form of vitamin B that is thought to enhance the cancer-killing effect of some chemotherapies.

In Orlando, there has been great variation in the medicine’s availability.

For example, M.D. Anderson Cancer Center Orlando has enough leucovorin to treat patients through the end of March, said Andrea Ledford, oncology pharmacy manager. But the treatment center had to ration the drug for a two-week period in December.

In other places, supplies vary on a weekly basis.

"It’s hit or miss. Some days we get it, other days we don’t," said Dr. Lee Zehngebot, a Florida Hospital oncologist. "This is not a disaster — it’s not like patients aren’t getting their chemotherapy — but it’s definitely something we don’t like to see."

The issue surfaced in December when one manufacturer, Bedford Laboratories in Ohio, experienced production "interruptions," according to e-mail responses from company spokesman Jason Kurtz.

He would not provide additional information on the cause of the delay. The FDA referred questions on the particulars back to the company.

Nonetheless, Bedford has been releasing new batches of leucovorin in recent weeks and is working to expand its production capabilities, Kurtz said.

At the same time, the drug’s other manufacturer is churning out significantly more product.

The company, Teva Pharmaceuticals, could be ready to meet 100 percent of the country’s demand for leucovorin within a few months if necessary, said spokeswoman Denise Bradley.

Teva makes leucovorin at a facility in Irvine, Calif. It takes about 30 days to produce a batch.

"At this point, we’re manufacturing at full capacity," she said. "We’re filling orders as they come in."

FDA spokeswoman Karen Riley agreed that the leucovorin shortage appears to be nearing a resolution. Riley said the government has been working closely with manufacturers when problems surface with any drugs deemed "medically necessary."

Though not required by law, companies often give the FDA advance warning when they become aware of issues that will affect supplies of a drug.

"It is FDA’s policy to help prevent or alleviate shortages ... since these can have significant public health consequences," Riley said. "We did not receive advance notice of this shortage, however."

Zehngebot said the temporary problems with leucovorin underscore the inherent vulnerabilities in the U.S. drug supply. Lack of raw materials, manufacturing problems and the long lead time needed to expand production of a drug can all affect the supply chain, the FDA noted in a 2002 report on shortages.

The complexity of the issues is not lost on DiFonzo. In the end, though, she just wants to know that she can get leucovorin at her next chemotherapy treatment. At her most recent session, she said that her dose was cut down to one-fourth the usual amount.

DiFonzo was diagnosed with colon cancer in 2006. It has spread to her liver and lung. She credits her medical care with keeping her going so far.

"I don’t know how long I’ll be around, so I just try to enjoy most of my days," DiFonzo said. "But I don’t want people forgetting about us (cancer patients) who need these drugs to live."